尿膀胱癌抗原检测诊断膀胱癌的Meta分析

郭毓鹏; 关红军; 董晶; 荣胜忠; 李晓霞

doi:10.13201/j.issn.1001-1420.2015.05.012

尿膀胱癌抗原检测诊断膀胱癌的Meta分析

- 1. 牡丹江医学院公共卫生学院流行病与卫生统计学教研室(黑龙江牡丹江, 157000);
- 2. 佳木斯大学公共卫生学院流行病与卫生统计学教研室
基金项目:
国家自然科学基金资助项目（编号81273162）

详细信息

通讯作者: 李晓霞,E-mail:lixx1963@126.com

中图分类号: R737.14

收稿日期: 2014-10-30

Urinary bladder cancer test in the diagnosis of bladder cancer: A meta analysis

- 1. Department of Epidemiology and Health Statistics, School of Public Health, Mudanjiang Medical college, Mudanjiang, heilongjiang, 157011, China;
- 2. Department of Epidemiology and Health statistics, School of Public Health, Jiamusi University

More Information

Corresponding author: LI Xiaoxia, E-mail: lixx1963@126.com

Received Date: 30 October 2014

摘要

摘要: 目的：系统评价尿膀胱癌抗原（urinary bladder cancer，UBC）检测对膀胱癌的诊断意义。方法：制定原始文献的纳入、排除标准及检索策略，检索Pubmed （1996年1月~2014年8月）、EMBase （1996年1月~2014年8月）、CNKI （1996年1月~2014年8月）、万方数据库（1996年1月~2014年8月）、维普数据库（1996年1月~2014年8月），收集UBC检测诊断膀胱癌的有关文献，用MetaDiSc1.4软件进行Meta分析。结果：共检索到相关研究文献53篇，对纳入符合标准的22篇文献进行Meta分析，共3 371人。异质性检验提示无阈值效应，但存在其他原因导致的异质性。用随机效应模型进行Meta分析。UBC检测诊断膀胱癌的敏感度为0.673，特异度为0.827，阳性似然比为3.447，阴性似然比为0.365，诊断优势比为9.993，综合受试者工作特征曲线下面积为0.8271，Q^*指数为0.7599。结论：UBC作为一种敏感度、特异性均较高的无创性尿膀胱肿瘤标志物，可以作为膀胱癌诊疗的重要辅助手段，可在今后的膀胱癌防治工作中发挥重要作用。
- 膀胱癌 /
- 尿膀胱癌抗原 /
- Meta分析
Abstract: Objective: To systematic review of urinary bladder cancer(UBC) test in the diagnosis of bladder cancer.Methods: Pubmed (1996.1-2014.8), EMBase (1996.1-2014.8), CNKI (1996.1-2014.8), WanFang (1996.1-2014.8), cqvip (1996.1-2014.8) were searched for studies about UBC in the diagnosis of bladder cancer. The search strategy was made according to the Collaborative Review Group search strategy. Data were extracted by two reviewers using the designed extraction form. The software MetaDiSc1.4 was used to review management and data analysis.Results: In total, 53 relevant studies were founded, of which 22 were included, with 3371 patients involved. Heterogeneity but threshold effect was found within these studies. A meta-analysis was performed using random effect model. Pooled accuracy indicators of sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio(LR-) and diagnostic odds ratio(DOR) of UBC were 0.673, 0.827, 3.447, 0.365, 9.993, respectively. Area under curve(AUC) of SROC curve of UBC was 0.8271, and Q-index was 0.7599.Conclusions: UBC had a good accuracy performance in the the diagnosis of bladder cancer, and could be an available and important adjunct in the the diagnosis of bladder cancer.
- bladder cancer /
- urinary bladder cancer /
- meta analysis

HTML全文

参考文献(32)

[1]	Jemal A, Bray F, Center M M, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61(2):69-90.
[2]	Donat S M.Evaluation and follow-up strategies for superficial bladder cancer[J].Urol Clin North Am, 2003, 30(4):765-776.
[3]	Dalbagni G, Herr H W.Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer[J].Urol Clin North Am, 2000, 27(1):137-146.
[4]	Whiting P, Rutjes A W, Reitsma J B, et al.The development of QUADAS:a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews[J].BMC Med Res Methodol, 2003, 3:25.
[5]	Jadad A R, Moore R A, Carroll D, et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary[J]?Control Clin Trials, 1996, 17(1):1-12.
[6]	Silén, Rizvi SS, Letocha H, et al.Evaluation of the UBC test in the urine of healthy individuals, patients with benign disorders and urinary bladder cancer[J].Oncol Rep, 2000, 7(6):1269-1274.
[7]	Sumi S, Arai K, Kitahara S, et al.Preliminary report of the clinical performance of a new urinary bladder cancer antigen test:comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder[J].Clin Chim Acta, 2000, 296(1-2):111-120.
[8]	Heicappell R, Schostak M, Müller M, et al.Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder[J].Scand J Clin Lab Invest, 2000, 60(4):275-282.
[9]	Sánchez-Carbayo M, Herrero E, Megías J, et al.Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder[J].Urology, 1999, 54(4):656-661.
[10]	Giannopoulos A, Manousakas T, Gounari A, et al.Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors[J].J Urol, 2001, 166(2):470-475.
[11]	Eissa S, Swellam M, Sadek M, et al.Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors[J].J Urol, 2002, 168(2):465-469.
[12]	Hakenberg O W, Fuessel S, Richter K, et al.Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma[J].Urology, 2004, 64(6):1121-1126.
[13]	Schroeder G L, Lorenzo-Gomez M F, Hautmann S H, et al.A side by side comparison of cytology and biomarkers for bladder cancer detection[J].J Urol, 2004, 172(3):1123-1126.
[14]	李涛, 何延瑜, 王颖, 等.膀胱癌抗原在膀胱移行细胞癌诊断中的价值[J].实用肿瘤学杂志, 2005, 19(1):18-21.
[15]	Bartoletti R, Dal Canto M, Cai T, et al.Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment[J].Oncol Rep, 2005, 13(3):531-537.
[16]	Shoshtari M A, Soleimani M, Moslemi M.Comparative evaluation of urinary bladder cancer antigen and urine cytology in the diagnosis of bladder cancer[J].Urol J, 2005, 2(3):137-140.
[17]	Kibar Y, Goktas S, Kilic S, et al.Prognostic value of cytology, nuclear matrix protein 22(NMP22) test, and urinary bladder cancer II(UBC II) test in early recurrent transitional cell carcinoma of the bladder[J].Ann Clin Lab Sci, 2006, 36(1):31-38.
[18]	May M, Hakenberg O W, Gunia S, et al.Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice[J].Urology, 2007, 70(3):449-453.
[19]	蒲小勇, 王志平, 陈一戎, 等.联合检测UBC、HA和CK20诊断膀胱癌的临床价值[J].癌症, 2008, 27(8):970-973.
[20]	陈华, 张华, 项明洁, 等.尿膀胱癌抗原、CYFRA21-1和透明质酸在膀胱癌诊断中的价值[J].诊断学理论与实践, 2008, 7(1):73-76.
[21]	李扬, 郑衍平, 许旭昀, 等.尿NMP22、UBC及BTA联合检测在膀胱癌早期诊断中的意义研究[J].国际检验医学杂志, 32(11):1187-1188.
[22]	张绍谨, 刘红耀.尿膀胱癌抗原、核基质蛋白22和透明质酸诊断膀胱癌的临床价值[J].中华临床医师杂志(电子版), 5(24):7202-7205.
[23]	周毅, 王伟, 姚远, 等.尿膀胱癌抗原、透明质酸和存活素联合检测对膀胱癌的诊断运用探讨[J].中国实验诊断学, 2012, 16(9):1661-1664.
[24]	Ritter R, Hennenlotter J, Kühs U, et al.Evaluation of a new quantitative point-of-care test platform for urinebased detection of bladder cancer[J].Urol Oncol, 2014, 32(3):337-344.
[25]	温儒民, 薛松, 马萍, 等.尿细胞角蛋白检测与尿脱落细胞学检查在膀胱癌诊断中的价值[J].中国癌症杂志, 15(6):575-576.
[26]	Guo A, Wang X, Gao L, et al.Bladder tumour antigen(BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer:A meta-analysis[J].Can Urol Assoc J, 2014, 8(5-6):E347-E352.
[27]	Shariat S F, Marberger M J, Lotan Y, et al.Variability in the performance of nuclear matrix protein 22for the detection of bladder cancer[J].J Urol, 2006, 176(3):919-926;discussion 926.
[28]	Konety B R, Nguyen T S, Dhir R, et al.Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4[J].Clin Cancer Res, 2000, 6(7):2618-2625.
[29]	Lokeshwar V B, Obek C, Pham H T, et al.Urinary hyaluronic acid and hyaluronidase:markers for bladder cancer detection and evaluation of grade[J].J Urol, 2000, 163(1):348-356.
[30]	Nisman B, Barak V, Shapiro A, et al.Evaluation of urine CYFRA 21-1for the detection of primary and recurrent bladder carcinoma[J].Cancer, 2002, 94(11):2914-2922.
[31]	刘云飞, 郑江, 刘昌茂, 等.核基质蛋白22及尿膀胱癌抗原在膀胱移行细胞癌诊断中的价值[J].中国综合临床, 2010, 26(1):80-82.
[32]	史沁兵, 唐晓磊.尿液中尿膀胱癌抗原和钙网蛋白联合检测对原发性膀胱癌的诊断价值[J].肿瘤基础与临床, 27(4):341-342.